Contents
-
news
-
Health
New drug lepodisiran expected to cut the risk of heart attack, stroke up to 94 percent
A dose of an experimental drug has been found to reduce the risk of genetic heart disease by at least 94 percent. Lapodisiran, developed by Ellie Lily, has shown promising results in reducing lipoprotein (A), or LP (A) levels, a test in a test and a genetically inherited particle associated with the increasing risk of heart attack and stroke. This protein is undesken by regular tests in the body and uncontrolled by existing drugs, diet, or exercise.
Lapodisiran reduces a small particle level known as LP (A). 94 with the same shot
A new experimental medicine, lepodisiran, millions of people are expected to protect against heart attacks and strokes by reducing slightly known risk factor in the blood. Manufactured by the pharmaceutical giant Eli Lily, the drug reduces a small particle level known as LP (A), 94 percent with the same shot, shown in a new study.
According to experts, LP (A) is a mixture of protein and lipids.
Research on lepodisiran said that its effect lasted for six months, with no major side effects. The study presented at an American College of Cardiology meeting in Chicago on Sunday was also published in the New England Journal of Medicine.
“If further tests suggest that this drug – lepodisiran – is safe and can reduce stroke, it will be good news for patients as it ends a risk factor that we have been unable to treat,” the chief study writer, Steve Nisen, MD, the main academic officer of the heart, and the thoracic institute in the Thoracic Institute was said to “This drug may be an injection of one year once as a vaccine for people with high LP (A) levels.”
Worldwide, it is estimated that 20–30 percent of people have increased LP (A) levels, which are usually considered above 30–50 mg/DL (or 125 NMOL/L), and are associated with increasing risk of heart diseases such as heart attacks and strokes. Doctors say that most people do not know that they have this.
Doctors have called intense and long -lasting decrease in lipoprotein levels with lepodisiran as “thrilling”. However, scientists say that further studies are also required to confirm that by reducing LP (A) that further reduces the risk of heart attack and stroke.
What is LP (A)?
According to experts, in 1974 LP (A) -Discoward – is mostly controlled by genes and not regulated by diet and exercise. People with slightly high levels have 25 percent more risk of heart disease, and people with much higher levels – for 10 percent of people – doubles the risk.
Doctors say that this is often the reason hidden behind a heart attack in young or healthy people.
A preventive cardiologist at Cleveland Clinic. Steven was involved in the lepodisiran trial of Nisen and Lily, says that whenever a person under the age of 40 comes to hospitals with heart attack, their LP (A) levels should be investigated first. They combined with high LP (A) people who need to treat all other heart risk factors, such as cholesterol and blood pressure.
How does lepodisiran work?
According to scientists involved in the test, lepodisiran, a small interference RNA (A), an important component in LP (A) particles neutralizes the messenger RNA involved in the production of epolipoprotein (A). And so, it reduces the production of LP (A).
The doctor asks to defeat a risk factor that is largely genetic, an extremely effective approach to interfere with genes – and that is designed to do lepodisiran.
Now get the latest news with health and braking news and top headlines worldwide.
Steven nisenThoracic instituteRoyal armyEllie lilyLepodisiranLepodisiran expected the risk of heart attack cutShockLPA levels elevate
